v3.26.1
SHARE-BASED COMPENSATION (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of share-based compensation options grants to employees and directors
   
2025
 
   
 
Number of options
   
Weighted average exercise price
 
Outstanding at beginning of the year
   
7,652,654
   
$
2.32
 
Granted
   
1,926,545
     
2.28
 
Exercised
   
(26,449
)
   
0.80
 
Forfeited
   
(170,250
)
   
2.07
 
Expired
   
(99,228
)
   
2.91
 
Outstanding at end of the year
   
9,283,272
   
$
2.32
 
Exercisable at end of the year
   
6,294,226
   
$
2.47
 
Schedule of fair value assumptions of option granted using Black-Scholes option-pricing model
   
2025
   
2024
 
Exercise price
 
$
2.28
   
$
0.60-$1.99
 
share price
 
$
2.28
   
$
0.60-$1.99
 
Dividend yield
   
-
     
-
 
Expected volatility 
   
81.2%-82.2
%
   
74.28%-84.5
%
Risk-free interest rate 
   
3.9%-4.45
%
   
3.93%-4.66
%
Expected life - in years 
   
5.3-5.87
     
5.3-5.9
 
Schedule of outstanding and exercisable options of ordinary shares
December 31, 2025
 
Options outstanding
   
Options exercisable
 
     
Number of
   
Weighted
   
Number of
   
Weighted
 
     
options
   
Average
   
options
   
Average
 
Exercise
   
outstanding
   
Remaining
   
exercisable
   
Remaining
 
prices per
   
at end of
   
Contractual
   
at end of
   
contractual
 
share (USD)
   
Year
   
Life
   
year
   
Life
 
                           
 
0.6-0.89
     
2,103,342
     
7.45
     
1,669,422
     
7.80
 
 
1.4-1.99
     
1,913,000
     
7.75
     
1,189,000
     
7.58
 
 
2.02-2.86
     
3,719,828
     
7.49
     
1,957,452
     
6.01
 
 
3.15-3.97
     
736,552
     
4.63
     
667,802
     
4.56
 
 
6.31
     
810,550
     
1.95
     
810,550
     
1.95
 
         
9,283,272
             
6,294,226
         
Schedule of RSUs information
   
Year ended December 31
 
   
2025
 
         
Weighted
 
   
Number
   
Average
 
   
of
   
Grant Date
 
   
RSUs
   
Fair Value
 
Outstanding at beginning of year
   
194,472
     
1.75
 
Changes during the year:
               
Granted
   
300,643
     
2.09
 
Vested
   
(352,134
)
   
1.92
 
Outstanding at end of year
   
142,981
     
2.06
 
Schedule of of share-based compensation on statements of operations
   
Year ended December 31, 2025
   
Year ended December 31, 2024
 
Cost of revenues
 
$
-
   
$
7
 
Research and development expenses
   
1,144
     
839
 
General and administrative
   
1,606
     
1,710
 
   
$
2,750
   
$
2,556